Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.
Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Brochet B, Audoin B, Mathey G, Laplaud D, Thouvenot E, Cohen M, Tourbah A, Maillart E, Ciron J, Deschamps R, Biotti D, Rostasy K, Neuteboom R, Hemingway C, Forsyth R, Matiello M, Webb S, Hunt D, Murray K, Hacohen Y, Lim M, Leite MI, Palace J, Solomon T, Lutterotti A, Fujihara K, Nakashima I, Bennett JL, Pandit L, Chitnis T, Weinshenker BG, Wildemann B, Sato DK, Kim SH, Huda S, Kim HJ, Reindl M, Levy M, Jarius S, Tenembaum S, Paul F, Pittock S, Marignier R, Jacob A. Whittam DH, et al. Among authors: cicconi s. Mult Scler Relat Disord. 2020 Sep;44:102251. doi: 10.1016/j.msard.2020.102251. Epub 2020 Jun 2. Mult Scler Relat Disord. 2020. PMID: 32629363 Free PMC article.
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J, Al-Mukhtar A, Dickson E, Graham J, Jiao L, Wasan HS, Tait IS, Prachalias A, Ross P, Valle JW, O'Reilly DA, Al-Sarireh B, Gwynne S, Ahmed I, Connolly K, Yim KL, Cunningham D, Armstrong T, Archer C, Roberts K, Ma YT, Springfeld C, Tjaden C, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Ghaneh P, et al. Among authors: cicconi s. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521500 Free article. Clinical Trial.
Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.
Hope W, Johnstone G, Cicconi S, Felton T, Goodwin J, Whalley S, Santoyo-Castelazo A, Ramos-Martin V, Lestner J, Credidio L, Dane A, Carr DF, Pirmohamed M, Salim R, Neely M. Hope W, et al. Among authors: cicconi s. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02353-18. doi: 10.1128/AAC.02353-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30670416 Free PMC article.
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells.
Linley AJ, Karydis LI, Mondru AK, D'Avola A, Al Shmrany H, Cicconi S, Griffin R, Forconi F, Pettitt AR, Kalakonda N, Rawstron AC, Hillmen P, Steele AJ, MacEwan DJ, Packham G, Prior IA, Slupsky JR. Linley AJ, et al. Among authors: cicconi s. Clin Cancer Res. 2021 Oct 15;27(20):5647-5659. doi: 10.1158/1078-0432.CCR-21-0161. Epub 2021 Aug 11. Clin Cancer Res. 2021. PMID: 34380642 Free PMC article.
SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol.
McCarthy C, Sacco J, Fedele S, Ho M, Porter S, Liloglou T, Greenhalf B, Robinson M, Young B, Cicconi S, Chauhan S, Tesfaye B, Jackson R, Sherratt F, Shaw R. McCarthy C, et al. Among authors: cicconi s. Trials. 2021 Jul 5;22(1):428. doi: 10.1186/s13063-021-05373-8. Trials. 2021. PMID: 34225765 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 32054653
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt AR, Jackson R, Cicconi S, Polydoros F, Yap C, Dodd J, Bickerstaff M, Stackpoole M, Khan UT, Carruthers S, Oates M, Lin K, Coupland SE, Menon G, Kalakonda N, McCarthy H, Bloor A, Schuh A, Duncombe A, Dearden C, Fegan C, Kennedy B, Walewska R, Marshall S, Fox CP, Hillmen P. Pettitt AR, et al. Among authors: cicconi s. Haematologica. 2020 Dec 1;105(12):2868-2871. doi: 10.3324/haematol.2019.230805. Haematologica. 2020. PMID: 33256390 Free PMC article. No abstract available.
58 results